 GAITHERSBURG, Md., Oct. 15, 2021 GLOBE NEWSWIRE -- Emergent BioSolutions Inc. NYSE:EBS today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the companys investigational chikungunya virus CHIKV virus-like particle VLP vaccine candidate, CHIKV VLP, in a single dose. CHIKV VLP is the only VLP-based vaccine currently in clinical development for active immunization against chikungunya disease. 